HRP20240319T1 - Pripravci i postupci za liječenje anemije - Google Patents
Pripravci i postupci za liječenje anemije Download PDFInfo
- Publication number
- HRP20240319T1 HRP20240319T1 HRP20240319TT HRP20240319T HRP20240319T1 HR P20240319 T1 HRP20240319 T1 HR P20240319T1 HR P20240319T T HRP20240319T T HR P20240319TT HR P20240319 T HRP20240319 T HR P20240319T HR P20240319 T1 HRP20240319 T1 HR P20240319T1
- Authority
- HR
- Croatia
- Prior art keywords
- days
- level
- measurement
- compound
- patient
- Prior art date
Links
- 208000007502 anemia Diseases 0.000 title claims 6
- 238000000034 method Methods 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title 1
- 102000001554 Hemoglobins Human genes 0.000 claims 27
- 108010054147 Hemoglobins Proteins 0.000 claims 27
- 238000005259 measurement Methods 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 25
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 14
- 229910052742 iron Inorganic materials 0.000 claims 7
- 102000003951 Erythropoietin Human genes 0.000 claims 6
- 108090000394 Erythropoietin Proteins 0.000 claims 6
- 208000020832 chronic kidney disease Diseases 0.000 claims 6
- 229940105423 erythropoietin Drugs 0.000 claims 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 230000003247 decreasing effect Effects 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 claims 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (16)
1. Spoj za uporabu u postupku za liječenje anemije sekundarne kroničnoj bubrežnoj bolesti kod subjekta ili anemije kod subjekta s kroničnom bubrežnom bolešću, pri čemu je spoj {[5-(3-klorofenil)-3-hidroksipiridin-2-ugljik-il]amino}octena kiselina, koja ima strukturu:
[image]
ili njegova farmaceutski prihvatljiva sol,
i pri čemu postupak uključuje oralnu primjenu spoja u dozi jednom dnevno od 100 mg do 800 mg.
2. Spoj za uporabu prema zahtjevu 1, naznačen time što je jednom dnevna doza 150 mg do 300 mg ili 300 mg do 600 mg.
3. Spoj za uporabu prema zahtjevu 1, naznačen time što je spoj pogodan za povećanje ukupnih razina eritropoetina u dnevnom obrascu.
4. Spoj za uporabu prema zahtjevu 3, naznačen time da su najniže razine eritropoetina povišene u usporedbi s najnižim razinama eritropoetina kod subjekta neposredno prije koraka primjene za najviše 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, ili 20%.
5. Spoj za uporabu prema zahtjevu 1, naznačen time što je kronična bolest bubrega stupanj 3, 4 ili 5 kronične bolesti bubrega.
6. Spoj za uporabu prema zahtjevima 1 ili 5, naznačen time što je kronična bubrežna bolest kronična bubrežna bolest prije dijalize.
7. Spoj za uporabu prema bilo kojem od zahtjeva 1-6, naznačen time što pacijent nije prethodno liječen od anemije; i/ili je pacijent otporan na liječenje rekombinantnim eritropoetinom; i/ili je pacijent prethodno liječen od anemije.
8. Spoj za uporabu prema bilo kojem od zahtjeva 1-6, naznačen time što su razine hemoglobina pacijenta
a. održavaju se na razini od najmanje 9.0 g/dL i na ili ispod 13.0 g/dL; ili
b. održavaju se na razini od najmanje 10.0 g/dL i na ili ispod 13.0 g/dL; ili
c. održavaju se na razini od najmanje 11.0 g/dL i na ili ispod 13.0 g/dL; ili
d. povećane su za najmanje 1.2 g/dL u odnosu na osnovnu razinu hemoglobina, poželjno je da se razine hemoglobina testiraju najmanje 1 dan, 2 dana, 3 dana, 4 dana, 5 dana, 6 dana, 7 dana, 8 dana, 9 dana, 10 dana, 11 dana, 12 dana, 13 dana, 14 dana, 3 tjedna, 4 tjedna, 5 tjedana, 6 tjedana, 7 tjedana, ili 8 tjedana nakon početne primjene spoja.
9. Spoj za uporabu prema bilo kojem od zahtjeva 1-8, naznačen time što postupak ne uključuje davanje dodatka željeza.
10. Spoj za uporabu prema bilo kojem od zahtjeva 1-9, naznačen time što se spoj primjenjuje jednom dnevno u isto doba dana, poželjno je da je doba dana ujutro ili rano poslijepodne.
11. Spoj za uporabu prema zahtjevu 1, naznačen time što postupak sadrži
a. davanje početne dnevne doze spoja pacijentu koji ima anemiju;
b. uzimanje prvog mjerenja razine hemoglobina kod pacijenta i naknadno uzimanje drugog mjerenja razine hemoglobina kod pacijenta, pri čemu
i. ako je razina hemoglobina kod pacijenta pri drugom mjerenju manja od 10.0 g/dL i ako je razina hemoglobina smanjena za manje od 0.5 g/dL u odnosu na razinu pri prvom mjerenju; ili
ii. ako je razina hemoglobina kod bolesnika pri drugom mjerenju manja od 10.0 g/dL i ako se razina hemoglobina promijenila do 0.4 g/dL u odnosu na razinu pri prvom mjerenju; ili
iii. ako je razina hemoglobina kod pacijenta pri drugom mjerenju između 10.0 i 10.9 g/dL i ako je razina hemoglobina smanjena za manje od 0.5 g/dL u odnosu na razinu pri prvom mjerenju; ili
iv. ako je razina hemoglobina kod pacijenta pri drugom mjerenju manja od 10.0 g/dL i ako je razina hemoglobina porasla za više od 1.5 g/dL u odnosu na razinu pri prvom mjerenju; ili
v. ako je razina hemoglobina kod pacijenta pri drugom mjerenju između 10.0 i 10.9 g/dL i ako je razina hemoglobina porasla za više od 1.5 g/dL u odnosu na razinu pri prvom mjerenju; ili
vi. ako je razina hemoglobina kod pacijenta pri drugom mjerenju između 11.0 i 12.2 g/dL i ako je razina hemoglobina porasla za između 1.0 i 1.4 g/dL u odnosu na razinu pri prvom mjerenju; ili
vii. ako je razina hemoglobina u pacijenta pri drugom mjerenju između 12.3 i 12.9 g/dL i razina hemoglobina se smanjila do 0.4 g/dL ili povećala do 0.4 g/dL u odnosu s prvim mjerenjem; ili
viii. ako je razina hemoglobina kod pacijenta pri drugom mjerenju između 12.3 i 12.9 g/dL i ako je razina hemoglobina porasla za 0.5 do 0.9 g/dL u odnosu na razinu pri prvom mjerenju; ili
ix. ako je razina hemoglobina kod pacijenta pri drugom mjerenju između 11.0 i 12.2 g/dL i ako je razina hemoglobina porasla za više od 1.5 g/dL u odnosu na razinu pri prvom mjerenju; ili
x. ako je razina hemoglobina kod pacijenta pri drugom mjerenju između 12.3 i 12.9 g/dL i ako je razina hemoglobina porasla za između 1.0 i 1.4 g/dL u odnosu na razinu pri prvom mjerenju; ili
xi. ako je razina hemoglobina kod pacijenta pri drugom mjerenju između 12.3 i 12.9 g/dL i ako je razina hemoglobina porasla za više od 1.5 g/dL u odnosu na razinu pri prvom mjerenju;
tada
c. davanje prilagođene dnevne doze spoja koje je veće od početne dnevne doze, poželjno 150 mg veća od početne dnevne doze.
12. Spoj za uporabu prema zahtjevu 11, naznačen time što je period između prvog i drugog mjerenja 1 dan, 2 dana, 3 dana, 4 dana, 5 dana, 6 dana, 7 dana, 8 dana, 9 dana, 10 dana, 11 dana, 12 dana, 13 dana, 14 dana, 3 tjedna, 4 tjedna, 5 tjedana, 6 tjedana, 7 tjedana, ili 8 tjedana.
13. Spoj za uporabu prema zahtjevu 11 ili 12, naznačen time što se prvo mjerenje vrši prije početka liječenja; ili odmah nakon početka liječenja ili unutar najviše 1 dana, 2 dana, 3 dana, 4 dana, 5 dana, 6 dana, ili 1 tjedna ,ili 2 tjedna nakon toga.
14. Spoj za uporabu prema bilo kojem od zahtjeva 1-13, naznačen time što se liječi bolest povezana sa smanjenom endogenom proizvodnjom eritropoetina (EPO), postupak sadrži davanje dovoljnog broja uzastopnih doza spoja 1, tako da se povisi ukupan kapacitet vezivanja željeza (TIBC) u odnosu na osnovni TIBC kod pacijenta, bez značajnog povećanja razine željeza u serumu u odnosu na početnu razinu željeza u serumu, poželjno pri čemu su kardiovaskularne nuspojave i rizik od tromboembolijskih događaja povezanih s povišenim razinama željeza u serumu svedeni na minimum.
15. Spoj za uporabu prema zahtjevu 14, naznačen time što se zasićenje transferina (TSAT) smanjuje u odnosu na osnovnu liniju TSAT, i/ili gdje se razina željeza u serumu smanjuje u odnosu na osnovnu razinu željeza u serumu, poželjno pri čemu se razina željeza u serumu povećava za manje od 20 µg/dL, manje od 15 µg/dL, manje od 10 µg/dL, ili manje od 5 µg/dL u odnosu na osnovnu razinu željeza u serumu; i/ili pri čemu se TIBC povećava za najmanje 10 µg/dL, 20 µg/dL, 30 µg/dL, 40 µg/dL, 50 µg/dL, ili najmanje 60 µg/dL u odnosu na osnovni TIBC, poželjno pri čemu povećanje TIBC-a događa se tijekom 1 tjedna, 2 tjedna, 3 tjedna, 4 tjedna, 5 tjedana, ili 6 tjedana u odnosu na početni TIBC.
16. Spoj za uporabu prema bilo kojem od zahtjeva 1-15, naznačen time što je spoj formuliran kao jedinični oblik doziranja koji sadrži 150 mg, 300 mg, ili 450 mg spoja.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361834808P | 2013-06-13 | 2013-06-13 | |
| US201361889478P | 2013-10-10 | 2013-10-10 | |
| US201361898890P | 2013-11-01 | 2013-11-01 | |
| US201361898885P | 2013-11-01 | 2013-11-01 | |
| US201361912185P | 2013-12-05 | 2013-12-05 | |
| PCT/US2014/040889 WO2014200773A2 (en) | 2013-06-13 | 2014-06-04 | Compositions and methods for treating anemia |
| EP14811317.8A EP3007695B1 (en) | 2013-06-13 | 2014-06-04 | Compositions and methods for treating anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240319T1 true HRP20240319T1 (hr) | 2024-05-24 |
Family
ID=52022903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240319TT HRP20240319T1 (hr) | 2013-06-13 | 2014-06-04 | Pripravci i postupci za liječenje anemije |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US11857543B2 (hr) |
| EP (2) | EP3007695B1 (hr) |
| JP (5) | JP2016521747A (hr) |
| KR (4) | KR102461176B1 (hr) |
| CN (3) | CN114404413A (hr) |
| AU (4) | AU2014278543B2 (hr) |
| BR (1) | BR112015031027A2 (hr) |
| CA (2) | CA2914662C (hr) |
| CL (2) | CL2015003602A1 (hr) |
| CY (2) | CY1126699T1 (hr) |
| DK (1) | DK3007695T3 (hr) |
| DO (1) | DOP2015000297A (hr) |
| EC (1) | ECSP20058592A (hr) |
| ES (1) | ES2974273T3 (hr) |
| FI (2) | FI3007695T3 (hr) |
| FR (1) | FR24C1025I2 (hr) |
| HR (1) | HRP20240319T1 (hr) |
| HU (2) | HUE066123T2 (hr) |
| IL (3) | IL243047B (hr) |
| LT (1) | LT3007695T (hr) |
| MX (3) | MX378150B (hr) |
| MY (1) | MY204336A (hr) |
| NL (1) | NL301278I2 (hr) |
| NO (1) | NO2024025I1 (hr) |
| NZ (3) | NZ714963A (hr) |
| PE (2) | PE20201496A1 (hr) |
| PH (2) | PH12015502738B1 (hr) |
| PL (1) | PL3007695T3 (hr) |
| PT (1) | PT3007695T (hr) |
| RS (1) | RS65341B1 (hr) |
| RU (2) | RU2705206C2 (hr) |
| SG (2) | SG11201509998WA (hr) |
| SI (1) | SI3007695T1 (hr) |
| SM (1) | SMT202400092T1 (hr) |
| TW (5) | TWI650126B (hr) |
| WO (1) | WO2014200773A2 (hr) |
| ZA (1) | ZA201509024B (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101506149B (zh) | 2006-06-26 | 2012-11-14 | 华纳奇考特有限责任公司 | 脯氨酰羟化酶抑制剂及使用方法 |
| NO2686520T3 (hr) | 2011-06-06 | 2018-03-17 | ||
| US10085661B2 (en) | 2013-04-16 | 2018-10-02 | Koninklijke Philips N.V. | System and method for biventricular pacemaker pulse detection in surface ECG |
| MY204336A (en) * | 2013-06-13 | 2024-08-23 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| WO2015073779A1 (en) | 2013-11-15 | 2015-05-21 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| WO2016118858A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| KR102647879B1 (ko) * | 2015-04-01 | 2024-03-15 | 아케비아 테라퓨틱스 인코포레이티드 | 빈혈 치료용 조성물 및 방법 |
| WO2018103600A1 (zh) * | 2016-12-06 | 2018-06-14 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的杂芳基酰胺化合物及包含该化合物的组合物及其用途 |
| WO2019028150A1 (en) * | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| JP7440989B2 (ja) | 2018-05-09 | 2024-02-29 | アケビア セラピューティクス インコーポレイテッド | ２－［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ］酢酸を調製するための方法 |
| JP2023501221A (ja) | 2019-10-31 | 2023-01-18 | アケビア セラピューティクス インコーポレイテッド | バダデュスタットを使用する治療方法 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| TW202207930A (zh) * | 2020-03-17 | 2022-03-01 | 印度商卡地拉保健有限公司 | 包含ｈｉｆ脯胺醯基羥化酶抑制劑之調和物 |
| KR20230017204A (ko) * | 2020-04-29 | 2023-02-03 | 바이오에이지 랩스, 인코포레이티드 | 노화-관련 질환 치료용 저산소증-유도 인자 프롤릴 히드록실라제 억제제 |
| US20230263786A1 (en) | 2020-06-19 | 2023-08-24 | Akebia Therapeutics, Inc. | Modulation of drug-drug interactions of vadadustat |
| WO2022150621A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Therapeutic methods using vadadustat |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| AU2022229275A1 (en) | 2021-03-01 | 2023-10-12 | Akebia Therapeutics, Inc. | Modulation of drug-drug interactions of vadadustat |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655679A (en) | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US3703582A (en) | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
| US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
| CA1261335A (en) | 1984-08-29 | 1989-09-26 | Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee | Ethylenediamine monoamide derivatives |
| CN1023479C (zh) | 1985-09-27 | 1994-01-12 | 弗·哈夫曼-拉罗切有限公司 | 乙二胺的单酰胺衍生物的制备方法 |
| TW219933B (hr) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE59401924D1 (de) | 1993-11-02 | 1997-04-10 | Hoechst Ag | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| EP0650960B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| TW406076B (en) | 1993-12-30 | 2000-09-21 | Hoechst Ag | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| CA2253282A1 (en) | 1996-04-30 | 1997-11-06 | Hoechst Aktiengesellschaft | 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CN1282319A (zh) | 1997-10-09 | 2001-01-31 | 小野药品工业株式会社 | 氨基丁酸衍生物 |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU757868B2 (en) | 1998-03-23 | 2003-03-06 | Aventis Pharmaceuticals Inc. | Piperididinyl and N-amidinopiperidinyl derivatives |
| GB9809213D0 (en) | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| AU753241C (en) | 1998-06-11 | 2003-05-08 | Pharmacia & Upjohn Company | Tablet formation |
| US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| EP1349531A1 (en) * | 2001-01-12 | 2003-10-08 | Sun Pharmaceuticals Industries Ltd. | Spaced drug delivery system |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| WO2002074981A2 (en) | 2001-03-21 | 2002-09-26 | Isis Innovation Ltd. | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
| US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| CA3094774A1 (en) * | 2001-12-06 | 2003-07-03 | Fibrogen, Inc. | Use of hif prolyl hydroxylase inhibitors for treating neurological disorders |
| WO2003097040A1 (en) | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| US7157100B2 (en) * | 2002-06-04 | 2007-01-02 | J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
| RU2005108667A (ru) | 2002-08-29 | 2005-08-27 | Мерк энд Ко., Инк. (US) | Производные n-биарилметиламиноциклоалканкарбоксамида |
| ES2337043T3 (es) | 2002-10-16 | 2010-04-20 | Isis Innovation Limited | Metodos de escrutinio empleando un modelo estructural de fih. |
| EP1567528A1 (en) | 2002-11-21 | 2005-08-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| PL1644336T3 (pl) | 2003-06-06 | 2011-07-29 | Fibrogen Inc | Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| NZ551632A (en) | 2004-05-28 | 2009-09-25 | Fibrogen Inc | HIF prolyl hydroxylase activity assay |
| WO2005115984A2 (en) | 2004-05-31 | 2005-12-08 | Tanabe Seiyaku Co., Ltd. | Large conductance calcium-activitated k channel opener |
| US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| WO2006084210A2 (en) | 2005-02-04 | 2006-08-10 | Regents Of The University Of California, San Diego | Hif modulating compounds and methods of use thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| JP5390184B2 (ja) | 2005-06-06 | 2014-01-15 | ファイブローゲン、インコーポレーテッド | 貧血の改良された治療方法 |
| CA2611785A1 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of hif 1alfa modulators for treatment of cancer |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| BRPI0615898B8 (pt) | 2005-09-12 | 2021-05-25 | Actelion Pharmaceuticals Ltd | composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| US20090176726A1 (en) | 2005-10-11 | 2009-07-09 | Fisher David E | Methods for treating mitf-related disorders |
| AU2006326662B2 (en) | 2005-12-09 | 2011-07-28 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| WO2007081835A2 (en) | 2006-01-09 | 2007-07-19 | Btg International Limited | Modulators of hypoxia inducible factor-1 and related uses |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
| US7625927B2 (en) | 2006-02-27 | 2009-12-01 | Alcon Research, Ltd. | Method of treating glaucoma |
| TW200808793A (en) | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| KR100798730B1 (ko) * | 2006-06-12 | 2008-01-29 | 신풍제약주식회사 | 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법 |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| CN101506149B (zh) * | 2006-06-26 | 2012-11-14 | 华纳奇考特有限责任公司 | 脯氨酰羟化酶抑制剂及使用方法 |
| CA2563690C (en) | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
| IES20070122A2 (en) | 2006-12-05 | 2008-05-28 | Michael Hilary Burke | A process for the preparation of an orally administered unit dose tablet |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| CA2682929A1 (en) | 2007-04-17 | 2008-10-23 | Ratiopharm Gmbh | Pharmaceutical compositions comprising irbesartan |
| AU2008241577B2 (en) | 2007-04-18 | 2011-04-07 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| CA2683758A1 (en) | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| EP2150251B9 (en) | 2007-05-04 | 2013-02-27 | Amgen, Inc | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| US8309544B2 (en) | 2007-05-16 | 2012-11-13 | Merck Sharp & Dohme Corp. | Spiroindalones |
| RU2009146851A (ru) | 2007-05-18 | 2011-06-27 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом |
| US8268794B2 (en) | 2007-08-06 | 2012-09-18 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| EP2188295A4 (en) | 2007-08-10 | 2011-11-16 | Crystalgenomics Inc | PYRIDINE DERIVATIVES AND METHODS OF USE |
| WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| NZ585701A (en) | 2007-11-30 | 2012-09-28 | Glaxosmithkline Llc | Benzopyrazine derivatives as prolyl hydroxylase inhibitors |
| EP2224926A4 (en) | 2007-11-30 | 2010-12-01 | Glaxosmithkline Llc | INHIBITORS OF PROLYL HYDROXYLASES |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| US20100298324A1 (en) | 2007-12-19 | 2010-11-25 | Smith Kline Beecham Corporation | Prolyl Hydroxylase Inhibitors |
| WO2009086592A1 (en) | 2008-01-04 | 2009-07-16 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| HRP20150892T1 (hr) | 2008-03-03 | 2015-09-25 | Novartis Ag | Spojevi i sastavi kao modulatori tlr-aktivnosti |
| JP2011528686A (ja) | 2008-07-23 | 2011-11-24 | エフ．ホフマン−ラ ロシュ アーゲー | ヘテロ環式抗ウイルス性化合物 |
| TW201006473A (en) | 2008-08-13 | 2010-02-16 | Orient Pharma Co Ltd | Bi-layer medicine tablet containing Zaleplon |
| NZ591394A (en) | 2008-09-15 | 2013-03-28 | Kasina Laila Innova Pharmaceuticals Private Ltd | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
| HU230877B1 (hu) * | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
| CN102272117B (zh) | 2008-11-14 | 2015-06-17 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| US8137666B2 (en) * | 2008-11-22 | 2012-03-20 | Academia Sinica | Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses |
| HRP20130846T1 (hr) | 2009-03-31 | 2013-11-22 | Kissei Pharmaceutical Co., Ltd. | Derivati indolizina i njihova uporaba u medicinske svrhe |
| WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| HRP20140705T1 (hr) | 2009-07-17 | 2014-09-12 | Japan Tobacco, Inc. | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
| MX2012005275A (es) | 2009-11-06 | 2012-06-19 | Aerpio Therapeutics Inc | Composiciones y metodos para tratar colitis. |
| WO2012097331A1 (en) | 2011-01-13 | 2012-07-19 | Fibrogen, Inc. | Methods for increasing reticulocyte hemoglobin content |
| NO2686520T3 (hr) | 2011-06-06 | 2018-03-17 | ||
| CA2837560C (en) | 2011-06-06 | 2017-02-14 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| US20130022974A1 (en) | 2011-06-17 | 2013-01-24 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| ES2606631T3 (es) | 2011-07-22 | 2017-03-24 | Beijing Betta Pharmaceuticals Co., Ltd | Formas polimeróficas de compuestos como inhibidor de la prolila hidroxilasa, y usos de los mismos |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| MY204336A (en) * | 2013-06-13 | 2024-08-23 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| KR20160046832A (ko) | 2013-08-16 | 2016-04-29 | 오하이오 스테이트 이노베이션 파운데이션 | Dna 메틸화 조절용 조성물 및 조절방법 |
| WO2015073779A1 (en) | 2013-11-15 | 2015-05-21 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| EP3096617A4 (en) | 2014-01-23 | 2017-09-13 | Akebia Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| WO2016118858A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| EP3270922A4 (en) | 2015-03-20 | 2018-08-01 | Akebia Therapeutics Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| KR102647879B1 (ko) | 2015-04-01 | 2024-03-15 | 아케비아 테라퓨틱스 인코포레이티드 | 빈혈 치료용 조성물 및 방법 |
| WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| WO2020072645A1 (en) | 2018-10-03 | 2020-04-09 | Akebia Therapeutics, Inc. | Benzimidazole derivative for use in the treatment of inflammatory disorders |
| US11524939B2 (en) * | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
-
2014
- 2014-06-04 MY MYPI2019003537A patent/MY204336A/en unknown
- 2014-06-04 FI FIEP14811317.8T patent/FI3007695T3/fi active
- 2014-06-04 AU AU2014278543A patent/AU2014278543B2/en active Active
- 2014-06-04 CA CA2914662A patent/CA2914662C/en active Active
- 2014-06-04 LT LTEPPCT/US2014/040889T patent/LT3007695T/lt unknown
- 2014-06-04 BR BR112015031027A patent/BR112015031027A2/pt not_active Application Discontinuation
- 2014-06-04 CN CN202111479723.0A patent/CN114404413A/zh active Pending
- 2014-06-04 SG SG11201509998WA patent/SG11201509998WA/en unknown
- 2014-06-04 CN CN201480045048.2A patent/CN105451739A/zh active Pending
- 2014-06-04 EP EP14811317.8A patent/EP3007695B1/en active Active
- 2014-06-04 JP JP2016519543A patent/JP2016521747A/ja active Pending
- 2014-06-04 SI SI201432066T patent/SI3007695T1/sl unknown
- 2014-06-04 KR KR1020217011294A patent/KR102461176B1/ko active Active
- 2014-06-04 PE PE2020000452A patent/PE20201496A1/es unknown
- 2014-06-04 PL PL14811317.8T patent/PL3007695T3/pl unknown
- 2014-06-04 NZ NZ714963A patent/NZ714963A/en unknown
- 2014-06-04 EP EP24156067.1A patent/EP4360706A3/en active Pending
- 2014-06-04 SG SG10201910773VA patent/SG10201910773VA/en unknown
- 2014-06-04 CA CA3151685A patent/CA3151685A1/en active Pending
- 2014-06-04 RU RU2016100363A patent/RU2705206C2/ru active
- 2014-06-04 RS RS20240271A patent/RS65341B1/sr unknown
- 2014-06-04 KR KR1020167000558A patent/KR102373245B1/ko active Active
- 2014-06-04 WO PCT/US2014/040889 patent/WO2014200773A2/en active Application Filing
- 2014-06-04 KR KR1020227037446A patent/KR102660040B1/ko active Active
- 2014-06-04 MX MX2015017229A patent/MX378150B/es unknown
- 2014-06-04 DK DK14811317.8T patent/DK3007695T3/da active
- 2014-06-04 KR KR1020247012967A patent/KR20240055172A/ko active Pending
- 2014-06-04 HU HUE14811317A patent/HUE066123T2/hu unknown
- 2014-06-04 NZ NZ753905A patent/NZ753905A/en unknown
- 2014-06-04 ES ES14811317T patent/ES2974273T3/es active Active
- 2014-06-04 CN CN202111479746.1A patent/CN114404414A/zh active Pending
- 2014-06-04 MX MX2020006963A patent/MX391198B/es unknown
- 2014-06-04 RU RU2019134558A patent/RU2019134558A/ru unknown
- 2014-06-04 SM SM20240092T patent/SMT202400092T1/it unknown
- 2014-06-04 PT PT148113178T patent/PT3007695T/pt unknown
- 2014-06-04 HR HRP20240319TT patent/HRP20240319T1/hr unknown
- 2014-06-04 PE PE2015002603A patent/PE20160194A1/es unknown
- 2014-06-04 NZ NZ753904A patent/NZ753904A/en unknown
- 2014-06-04 US US14/897,849 patent/US11857543B2/en active Active
- 2014-06-13 TW TW103120661A patent/TWI650126B/zh active
- 2014-06-13 TW TW109141639A patent/TWI791177B/zh active
- 2014-06-13 TW TW111149765A patent/TWI856464B/zh active
- 2014-06-13 TW TW107141589A patent/TWI712411B/zh active
- 2014-06-13 TW TW113131294A patent/TW202446394A/zh unknown
-
2015
- 2015-12-07 PH PH12015502738A patent/PH12015502738B1/en unknown
- 2015-12-08 DO DO2015000297A patent/DOP2015000297A/es unknown
- 2015-12-10 ZA ZA2015/09024A patent/ZA201509024B/en unknown
- 2015-12-10 IL IL24304715A patent/IL243047B/en active IP Right Grant
- 2015-12-11 CL CL2015003602A patent/CL2015003602A1/es unknown
- 2015-12-11 MX MX2022003510A patent/MX2022003510A/es unknown
-
2018
- 2018-08-17 CL CL2018002372A patent/CL2018002372A1/es unknown
-
2019
- 2019-05-14 JP JP2019091113A patent/JP6612479B2/ja active Active
- 2019-10-30 JP JP2019197138A patent/JP6937812B2/ja active Active
- 2019-10-31 IL IL270335A patent/IL270335B/en active IP Right Grant
-
2020
- 2020-02-07 AU AU2020200903A patent/AU2020200903B2/en active Active
- 2020-09-17 EC ECSENADI202058592A patent/ECSP20058592A/es unknown
- 2020-10-15 PH PH12020551705A patent/PH12020551705A1/en unknown
-
2021
- 2021-02-23 IL IL281058A patent/IL281058B2/en unknown
- 2021-08-31 JP JP2021140772A patent/JP7328291B2/ja active Active
-
2022
- 2022-01-28 AU AU2022200570A patent/AU2022200570B2/en active Active
-
2023
- 2023-08-03 JP JP2023127201A patent/JP7672455B2/ja active Active
- 2023-11-16 US US18/511,042 patent/US20240335434A1/en active Pending
-
2024
- 2024-03-08 CY CY20241100181T patent/CY1126699T1/el unknown
- 2024-05-29 NO NO2024025C patent/NO2024025I1/no unknown
- 2024-06-03 NL NL301278C patent/NL301278I2/nl unknown
- 2024-06-04 CY CY2024016C patent/CY2024016I1/el unknown
- 2024-06-07 FR FR24C1025C patent/FR24C1025I2/fr active Active
- 2024-06-25 FI FIC20240023C patent/FIC20240023I1/fi unknown
- 2024-07-02 HU HUS2400023C patent/HUS2400023I1/hu unknown
- 2024-07-30 AU AU2024205219A patent/AU2024205219A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240319T1 (hr) | Pripravci i postupci za liječenje anemije | |
| HRP20210686T1 (hr) | Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom | |
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| JP2013522303A5 (hr) | ||
| JP2015519404A5 (hr) | ||
| JP2019031567A5 (hr) | ||
| SMP200700047B (it) | Forme di dosaggio di risedronato | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| RU2015127794A (ru) | Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в | |
| JP2015535209A5 (hr) | ||
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2017533972A5 (hr) | ||
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2012502103A5 (hr) | ||
| JP2012511510A5 (hr) | ||
| JP2015522015A5 (hr) | ||
| JP2017536380A (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| RU2011113762A (ru) | Способы применения композиций с замедленным высвобождением аминопиридина | |
| FI2683245T4 (fi) | Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä | |
| FI3634396T3 (fi) | Koostumus L-DOPA-hoidon tehon parantamiseen | |
| JP2019507786A5 (hr) | ||
| JP2016505050A5 (hr) | ||
| JP2019532112A5 (ja) | 結節性痒疹を治療するための抗掻痒剤 | |
| JP2004002429A5 (hr) |